{
    "clinical_study": {
        "@rank": "127654", 
        "arm_group": [
            {
                "arm_group_label": "Treatment sequence AB", 
                "arm_group_type": "Experimental", 
                "description": "Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER"
            }, 
            {
                "arm_group_label": "Treatment sequence BA", 
                "arm_group_type": "Experimental", 
                "description": "Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the bioequivalence of a newly developed ULTRACET\n      extended-release (ER) tablet of tramadol hydrochloride and acetaminophen, to the current\n      marketed ULTRACET ER tablet, in healthy participants under fasted condition."
        }, 
        "brief_title": "A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed an informed consent document indicating they understand the purpose of and\n             procedures required for the study and are willing to participate\n\n          -  Must agree to use an adequate contraception method as deemed appropriate by the\n             investigator (e.g., vasectomy, double-barrier, partner using effective contraception)\n             and to not donate sperm during the study and for 3 months after receiving the last\n             dose of study drug\n\n          -  Body mass index (weight [kg]/height2 [m]2) between 18.5 and 30 kg/m2 (inclusive), and\n             body weight not less than 50 kg\n\n          -  Blood pressure (after the participant is sitting for 5 minutes) between 90 and 140 mm\n             Hg systolic, inclusive, and no higher than 90 mm Hg diastolic\n\n          -  A 12-lead electrocardiogram (ECG) consistent with normal cardiac function, including\n             sinus rhythm, pulse rate between 45 and 90 bpm, QTc interval <= 450 ms, QRS interval\n             of <110 ms, PR interval <200 ms, and morphology consistent with healthy cardiac\n             function\n\n        Exclusion Criteria:\n\n          -  History of or current clinically significant medical illness including (but not\n             limited to) cardiac arrhythmias or other cardiac disease, hematologic (blood)\n             disease, coagulation disorders (including any abnormal bleeding), lipid\n             abnormalities, significant lung disease (including bronchospastic respiratory\n             disease), diabetes mellitus, kidney or liver insufficiency, thyroid disease,\n             neurologic or psychiatric disease, infection, or any other illness that the\n             investigator considers should exclude the participant or that could interfere with\n             the interpretation of the study results\n\n          -  Clinically significant abnormal values for hematology, clinical chemistry or\n             urinalysis at screening or at admission to the study center as deemed appropriate by\n             the investigator\n\n          -  Clinically significant abnormal physical examination, vital signs or 12-lead ECG at\n             screening (or at admission to the study center) as deemed appropriate by the\n             investigator\n\n          -  Use of any prescription or nonprescription medication (including vitamins and herbal\n             supplements), except for oral contraceptives and hormonal replacement therapy within\n             14 days before the first dose of the study drug is scheduled\n\n          -  History of, or reason to believe a participant has a history of, drug or alcohol\n             abuse within the past 5 years"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01778075", 
            "org_study_id": "CR100924", 
            "secondary_id": "TRAMCTPAI1003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment sequence AB", 
                    "Treatment sequence BA"
                ], 
                "description": "Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.", 
                "intervention_name": "Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment sequence AB", 
                    "Treatment sequence BA"
                ], 
                "description": "Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.", 
                "intervention_name": "Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Tramadol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy", 
            "Ultracet extended release (ER)", 
            "Tramadol hydrochloride", 
            "Acetaminophen", 
            "Bioequivalence"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "link": {
            "description": "A Single-Dose, Open-Label, Randomized, Two-Way Crossover Pivotal Study to Assess the Bioequivalence of a New ULTRACET ER Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Conditions", 
            "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=3592&filename=CR100924_CSR.pdf"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Dose, Open-Label, Randomized, Two-Way Crossover Pivotal Study to Assess the Bioequivalence of a New ULTRACET ER Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition", 
        "overall_official": {
            "affiliation": "Janssen Korea, Ltd., Korea", 
            "last_name": "Janssen Korea, Ltd., Korea Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Plasma concentrations of racemic tramadol (Period 1)", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours following the administration of study drug on Day 1 of Period 1"
            }, 
            {
                "measure": "Plasma concentrations of acetaminophen (Period 1)", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours following the administration of study drug on Day 1 of Period 1"
            }, 
            {
                "measure": "Plasma concentrations of racemic tradamdol (Period 2)", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours following the administration of study drug on Day 1 of Period 2"
            }, 
            {
                "measure": "Plasma concentrations of acetaminophen (Period 2)", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours following the administration of study drug on Day 1 of Period 2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01778075"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of adverse events as a measure of safety and tolerability", 
            "safety_issue": "No", 
            "time_frame": "Approximately 5 weeks"
        }, 
        "source": "Janssen Korea, Ltd., Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Korea, Ltd., Korea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}